Home Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
 

Keywords :   


Ligand Earns Milestone from SAGE Therapeutics for SAGE-547

2015-04-22 21:34:03| Biotech - Topix.net

Ligand Pharmaceuticals Incorporated today announced that it has earned a $500,000 milestone payment from SAGE Therapeutics relating to the treatment of the first patient in SAGE's Phase 3 open-label expanded access protocol, designated Study 302. Study 302 is designed to offer SAGE-547 to patients affected by super-refractory status epilepticus and to evaluate the safety of SAGE-547 in patients with SRSE.

Tags: sage milestone earns therapeutics

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11
27.11PSA10 SSP
27.11
27.11
27.11
27.115
27.11BTR 20()competition
27.11DVD
More »